<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

Melanoma PDX Models 
A Champions Model Cohort

Advance your Melanoma drug development research using an extensive bank of meticulously curated Melanoma PDX models directly established from primary  patient tumors. 

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

 

Advance your Melanoma Therapeutic Pipeline with Confidence 

Champions Oncology has established a large cohort of patient Melanoma PDX models, with 47* models available to scientists for melanoma research and drug development. These models are derived from patients with late-stage, metastatic, and heavily pretreated patients while retaining critical molecular features and alterations, making them therapeutically relevant.  (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Melanoma PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to one of the largest  bank of Melanoma PDX models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like Vemurafenib, Carboplatin, Ipilimumab, and more.